
    
      Patients with pathological confirmed non-small cell lung cancer with no standard treatment
      are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of
      targeted therapy where applicable. This is a prospective exploratory trial. Patients'
      rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens
      are identified. DC is in vitro primed with synthesized peptides. Both adverse events and
      responses are recorded.
    
  